Skip to main content
ESPR logo

ESPR

Esperion Therapeutics, Inc.

$3.18

0.31%

Trade Ideas Performance

Latest Closed Trade Idea

$3.18

0.31%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

0

Social

0

About

Events of Esperion Therapeutics, Inc. (ESPR)

Esperion announced a definitive agreement to be acquired by ARCHIMED, leading to analyst downgrades. The company reported its First Quarter 2026 financial results, missing EPS and revenue estimates. Esperion completed the acquisition of Corstasis Therapeutics. Piper Sandler initiated coverage of Esperion with an "Overweight" rating. Esperion reported its Fourth Quarter and Full Year 2025 financial results, marking a swing to profit. Analysis indicated that Esperion was in a "holding phase" awaiting U.S. guideline inclusion.

Read more

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Esperion Therapeutics, Inc. (ESPR) Live Stock Price, Chart & Financial News | Edge Hound